TREM2 and neoplasm: As noted, TREM2 expression by myeloid cells can impact T cell activation and proliferation; thus, it is not surprising that TREM2 may be able to serve as a biomarker for tumor burden and high TREM2 expression may confer resistance to immune checkpoint therapy (ICT).